Relieves discomfort associated with acute, painful musculoskeletal conditions. ANDA 40792, held by Aurobindo Pharma. Carisoprodol.
As of Nov 16, 2026, ANDA 40792 (Carisoprodol), held by Aurobindo Pharma, was first approved by FDA on Aug 6, 2009, with 7 approved supplements and 0 published complete response letters.
Carisoprodol tablets are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Limitation of Use Carisoprodol tablets should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 6, 2009 | Original application | Approved | None posted |
| Carisoprodol350MG · tablet;oral | Carisoprodol | Rx |
| Carisoprodol250MG · tablet;oral | Carisoprodol | Rx |
| Nov 13, 2018 | Supplement 14Labeling · Standard review | Approved | None posted |
| Oct 26, 2018 | Supplement 12Manufacturing | Approved | None posted |
| Nov 8, 2016 | Supplement 6Manufacturing · Standard review | Approved | None posted |
| May 2, 2013 | Supplement 4Labeling | Approved | None posted |
| Apr 30, 2013 | Supplement 9Labeling · Standard review | Approved | None posted |
| Mar 10, 2010 | Supplement 1Manufacturing | Approved | None posted |
| Mar 3, 2010 | Supplement 2Labeling | Approved | None posted |
| Aug 6, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters